# Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

> **NCT00521586** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1116 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** 13 valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 13 valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT00521586
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 1116 (ACTUAL)
- **Last updated:** 2015-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521586, "Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00521586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*